Source: Medscape Newsletter Feb 12, 2008
Antiepileptic Drugs Linked to Increased Risk for Suicidality
February 1, 2008 ? Patients receiving antiepileptic drugs (AEDs) that are also used to treat psychiatric disorders are about twice as likely to experience suicidality compared with those receiving placebo, the US Food and Drug Administration (FDA) warned healthcare professionals yesterday.
An analysis of data from 199 placebo-controlled studies of 11 different antiepileptic drugs (N = 43,892) revealed that patients receiving AEDs were significantly more likely to experience suicidal behavior or ideation compared with placebo (0.43% vs 0.22%; 2:1 per 1000 patients; 95% confidence interval, 0.7 ? 4.2). Four of the patients receiving antiepileptic therapy committed suicide, compared with none in the placebo group.
An increased risk for suicidality was observed as early as 1 week following initiation of therapy and continued through at least 24 weeks, according to an alert issued by MedWatch, the FDA's safety information and adverse event reporting program. Because most trials did not extend beyond this period, the risk for suicidality after 2 weeks could not be assessed reliably.
Results were generally consistent among the 11 drugs studied, and the relative risk (RR) vs placebo was higher in patients receiving treatment for epilepsy (RR = 3.6) than for selected psychiatric illnesses (RR = 1.6) or other conditions (eg, migraine and neuropathic pain; RR = 2.0).
AEDs included in the analysis included carbamazepine (Carbatrol, Shire US, Inc; Equetro, Validus Pharmaceuticals; and Tegretol/Tegretol XR, Novartis Pharmaceuticals Corp), felbamate (Felbatol, MedPoint Pharmaceuticals), gabapentin (Neurontin, Pfizer, Inc), lamotrigine (Lamictal, GlaxoSmithKline), levetiracetam (Keppra, UCB, Inc), oxcarbazepine (Trileptal, Novartis), pregabalin (Lyrica, Pfizer); tiagabine (Gabitril, Cephalon, Inc), topiramate (Topamax, Ortho-McNeil Pharmaceutical, Inc), valproate (Depakote/Depakote ER, Depakene, and Depacon, Abbott Laboratories), and zonisamide (Zonegran, Eisai, Inc, under license from Dainippon Pharmaceutical Company Ltd). Some of these medications are also marketed in generic form.
The FDA notes that the increased risk for suicidality is likely to apply to all AEDs and anticipates broad application of class labeling changes, which will be discussed at an upcoming advisory committee meeting.
In the interim, all patients currently taking or beginning therapy with antiepileptic drugs should be closely monitored for notable behavioral changes that could indicate the emergence or worsening of suicidal thoughts, behavior, or depression. Symptoms such as anxiety, agitation, hostility, mania, or hypomania may be precursors to emerging suicidality, the FDA said.
Healthcare providers are advised to balance the risk for suicidality with clinical need for treatment and to alert patients and their families/caregivers regarding the need to report unusual behavioral changes.
Adverse events related to AED therapy should be reported to the FDA's MedWatch reporting program:
telephone at 1-800-FDA-1088,
fax at 1-800-FDA-0178,
online at FDA/MedWatch Home Page,
mail to 5600 Fishers Lane, Rockville, MD 20852-9787
Antiepileptic Drugs Linked to Increased Risk for Suicidality
February 1, 2008 ? Patients receiving antiepileptic drugs (AEDs) that are also used to treat psychiatric disorders are about twice as likely to experience suicidality compared with those receiving placebo, the US Food and Drug Administration (FDA) warned healthcare professionals yesterday.
An analysis of data from 199 placebo-controlled studies of 11 different antiepileptic drugs (N = 43,892) revealed that patients receiving AEDs were significantly more likely to experience suicidal behavior or ideation compared with placebo (0.43% vs 0.22%; 2:1 per 1000 patients; 95% confidence interval, 0.7 ? 4.2). Four of the patients receiving antiepileptic therapy committed suicide, compared with none in the placebo group.
An increased risk for suicidality was observed as early as 1 week following initiation of therapy and continued through at least 24 weeks, according to an alert issued by MedWatch, the FDA's safety information and adverse event reporting program. Because most trials did not extend beyond this period, the risk for suicidality after 2 weeks could not be assessed reliably.
Results were generally consistent among the 11 drugs studied, and the relative risk (RR) vs placebo was higher in patients receiving treatment for epilepsy (RR = 3.6) than for selected psychiatric illnesses (RR = 1.6) or other conditions (eg, migraine and neuropathic pain; RR = 2.0).
AEDs included in the analysis included carbamazepine (Carbatrol, Shire US, Inc; Equetro, Validus Pharmaceuticals; and Tegretol/Tegretol XR, Novartis Pharmaceuticals Corp), felbamate (Felbatol, MedPoint Pharmaceuticals), gabapentin (Neurontin, Pfizer, Inc), lamotrigine (Lamictal, GlaxoSmithKline), levetiracetam (Keppra, UCB, Inc), oxcarbazepine (Trileptal, Novartis), pregabalin (Lyrica, Pfizer); tiagabine (Gabitril, Cephalon, Inc), topiramate (Topamax, Ortho-McNeil Pharmaceutical, Inc), valproate (Depakote/Depakote ER, Depakene, and Depacon, Abbott Laboratories), and zonisamide (Zonegran, Eisai, Inc, under license from Dainippon Pharmaceutical Company Ltd). Some of these medications are also marketed in generic form.
The FDA notes that the increased risk for suicidality is likely to apply to all AEDs and anticipates broad application of class labeling changes, which will be discussed at an upcoming advisory committee meeting.
In the interim, all patients currently taking or beginning therapy with antiepileptic drugs should be closely monitored for notable behavioral changes that could indicate the emergence or worsening of suicidal thoughts, behavior, or depression. Symptoms such as anxiety, agitation, hostility, mania, or hypomania may be precursors to emerging suicidality, the FDA said.
Healthcare providers are advised to balance the risk for suicidality with clinical need for treatment and to alert patients and their families/caregivers regarding the need to report unusual behavioral changes.
Adverse events related to AED therapy should be reported to the FDA's MedWatch reporting program:
telephone at 1-800-FDA-1088,
fax at 1-800-FDA-0178,
online at FDA/MedWatch Home Page,
mail to 5600 Fishers Lane, Rockville, MD 20852-9787
